Daniel J. Levendowski (United States of America)
Advanced Brain Monitoring, Inc.
Sleep and Respiratory
Daniel Levendowski has over 30 years of experience managing clinical research and developing and commercializing new technologies. He is co-inventor of 23 patented and 4 patent-pending technologies. His inventions include novel biomarker for identification of prodromal risk and/or severity of neurodegenerative disorders and delirium. He served as principal investigator for grants awarded by the National Institutes of Health, that totaled more than $8 million of research. His contributions in development and validation of a novel home sleep apnea test, a technology now used on over 2 mm patients worldwide, influenced the Center for Medicare Services and United Healthcare’s coverage decisions. His capabilities in commercializing new medical products, through the development of novel algorithms, conducting clinical trials and publishing the finding, have resulted in the successfully commercialization of numerous sleep medicine technologies, including the Sleep Profiler, Night Shift, Apnea Guard. The American Academy of Dental Sleep Medicine awarded Mr. Levendowski its Clinical Excellence Award In 2019, and Clinical Research Awards in both 2019 and 2020. He was the keynote speaker at the American Academy of Sleep Technologists meeting in 2017.

Presenter of 1 Presentation

 Conference Calendar

NON-REM SLEEP HYPERTONIA IN PARKINSONIAN-SPECTRUM DISORDERS

Session Name
1670 - EEG, SLEEP AND ELECTROPHYSIOLOGY (ID 207)
Session Type
SYMPOSIUM
Date
Sat, 19.03.2022
Session Time
02:45 PM - 04:45 PM
Room
ONSITE: 131-132
Lecture Time
02:45 PM - 03:00 PM
Presenter

Abstract

Aims

Non-REM sleep with hypertonia (NRH) is independently associated with synucleinopathy-mediated Parkinson-spectrum disorders (PSD), including dementia with Lewy Bodies/Parkinson’s Disease Dementia (DLB/PDD), Parkinson’s Disease (PD), and isolated REM sleep behavior disorder (iRBD). We sought to evaluate NRH in PSDs mediated by progressive supranuclear palsy (PSP) which is instead caused by tau pathology.

Methods

In this multicenter study, NRH in Parkinsonian-spectrum disorders DLB/PDD (n=15), PD (n=14), iRBD(n=19), and PSP (n=13) was compared to similar age-sex subjects with Alzheimer’s Disease (AD, n=22), mild cognitive impairment (MCI, n=35), and normal cognition (NC, n=61). In-home Sleep Profiler studies were attempted in all participants except iRBD patients, who had a single-night, in-laboratory SP recording. NRH was weighted-averaged in the 84% of in-home studies with two-nights of data. Statistical analyses included multiple logistic regression, receiver-operating-characteristic curves (ROC), and inter-class correlations (ICC).

Results

Abnormal NRH was detected in PSD with PSP=92%, DLB/PDD=80%, iRBD=74%, and PD=64%, compared to AD=14%, MCI=23%, and NC=16% (P<0.0001). Abnormal NRH differentiated the two groups with an area under the curve of 0.79 (95%CI: 0.73-0.85), a sensitivity of 0.76 (95%CI: 0.64-0.85) and a specificity of 0.82 (85%CI: 0.74-0.88). NRH demonstrated strong between-night (ICC=0.83, n=125) and >360-day test-retest (ICC=0.87, n=29) reliabilities.

Conclusions

NRH independently discriminated PSDs from age-sex similar non-PSD patients, suggesting that NRH is a common sleep motor signature across clinical PSD phenotypes. We speculate that NRH could be related to pathological changes within the substantia nigra (SNr) given common involvement of this key non-REM sleep motor modulating center in synucleinopathies and PSP.

Hide